Skip to main content
. 2020 Sep 25;11(2):597–621. doi: 10.1016/j.jcmgh.2020.09.012

Figure 8.

Figure 8

Relative expressions of TTP (ZFP36) and HuR (ELAVL1) in HCC patients. (A) ELAVL1 mRNA levels in human HCC GEO datasets. Data are represented as mRNA fold change between tumoral and non-tumoral tissues. Percentages of patients having more than 1.5-fold increase in ELAVL1 expression in tumors are indicated. (B) Percentage of HCC patients having low ZFP36 and high ELAVL1 levels based on GEO datasets from (A). (C) Survival analyses of HCC patients stratified based on ZFP36 and ELAVL1 mRNA expression levels (80th percentile). P value was calculated using a log-rank test (data retrieved from TCGA and Human Protein Atlas). ∗∗∗P < .001, ∗∗P < .01, ∗P < .05.